PluroGen

PluroGen will present findings of a newly published study on 1,036 patients which has resulted in an unprecedented 70% of the participants achieving wound closure. PluroGen will be showcasing their line of PluroGel Micelle Matrix Products in Florence.

PluroGen Therapeutics, LLC, a biotech company that provides clinically advanced topical products for chronic (non-healing) wounds and burns, today announced that the United States Patent and Trademark Office has issued US Patent #9,283,278 covering the...

PluroGen Therapeutics, LLC, an emerging leader in advanced wound care solutions, announced today that it will attend the European Wound Management Association (EWMA) Conference in Bremen, Germany, May 11 - 13, 2016.